The candidate had to survive more than a binding calculation
BioTwin developed a computational covalent candidate program for Lp(a). The work examined access to the relevant site, local reactivity, competing plasma chemistry, linker geometry and the relationship between molecular engagement and the intended effect.
- Structure changes the design · A site or attachment geometry must be assessed in the molecular context that matters.
- Chemistry meets competition · Reactivity must be considered alongside albumin, hydrolysis and other competing losses.
- Kinetics changes the objective · Capture, reversal, production and clearance determine what a proposed mechanism can sustain.
A corrected geometry reopened the design
An early domain-center distance had made a bivalent design appear out of reach. The relevant pocket-to-attachment geometry reopened that option. A later kinetic and regimen comparison favored continuing a simpler covalent design, while keeping the bivalent branch available.
A separate analysis found that reversible capping without clearance would not sustain lowering under its assumptions. That finding constrained one mechanism; it did not end the covalent program.
- Reversible-covalent kinetics · Compare the rates that determine sustained engagement and effect. Kinetic Amplification and Reversible-Covalent Regimes
- Plasma competition · Identify which competing process most strongly constrains a candidate. Plasma Competition and Covalent Capture
- Productive linker geometry · Test an architecture against reach and conformational requirements. Tether Conformer Reach and Productive Geometry
What the clinical result changes
On September 4, 2026, Novartis reported that pelacarsen’s Lp(a)HORIZON trial missed its primary cardiovascular endpoint despite lowering Lp(a). This finding raises questions for future research about intervention, measurement and clinical benefit; it does not establish which alternative mechanism would work.
- Read the sponsor’s topline report · The announcement states that detailed trial data will be presented at a medical congress. Novartis, September 4, 2026
An experiment that separates the mechanisms
A proposed evaluation would distinguish changes in intact particles, free and bound apo(a), associated cargo and functional effects. Those measurements could help separate a change in a biomarker from the biological change the intervention is meant to produce. The assay plan depends on the candidate mechanism and access to suitable samples.
Ready for molecular and biological testing
The program has computational candidate designs and mechanism analyses. Binding, biological activity and therapeutic benefit require experimental evidence. We are interested in partners who can help test the relevant molecular and functional questions.